Ben Beneski

Ben Beneski serves as Chief Technical Officer (CTO) at Allogene Therapeutics. Allogene Therapeutics operates in the biotechnology sector with approximately 260.0 employees. The company is headquartered in San Francisco, California. Allogene Therapeutics generates annual revenue of 22000.0.

Industry & Role Insights

• • MessageCEO tracks 381 executives in the biotechnology sector.
• • 13,743 executive contacts are available in California.
• • Our database includes 201,469 c suite-level executives.

Outlook Microsoft Office 365 Google Font API Gravity Forms Mobile Friendly Google Tag Manager Facebook Custom Audiences Nginx Open AdStream (Appnexus) Facebook Widget Facebook Login (Connect) Vimeo Google Analytics Linkedin Marketing Solutions WordPress.org Render Micro IoT Remote AI

oncology cancer biotechnology immunotherapy car t autoimmune biotechnology: biological products (no diagnostic substances) health care allocar t cell therapy autoimmune disease cancer treatment chimeric antigen receptor off-the-shelf investigational products multiplex gene-editing lymphodepletion clinical trials phase 1 trial phase 2 trial fda designation therapeutic advancements allogeneic car t manufacturing capabilities drug development patient access innovative medicines cancer immunotherapy treatment optimization commercialization strategy research & development preclinical data cemacabtagene ansegedleucel allo-316 allo-329 dual car t gene editing clinical-stage company management team investment opportunities financial results stock information corporate governance scientific publications healthcare conferences biopharmaceutical innovations on-demand therapy publications regenerative medicine disease targets therapeutic candidates clinical effectiveness patient-centric approach pipeline strategy collaborative research business development allogeneic car t cell therapy off-the-shelf treatments autoimmune diseases hematological malignancies solid tumors multiplex gene editing proprietary lymphodepletion platform innovative biotechnology patient accessibility scalable manufacturing fda fast track designation diversity & inclusion healthcare providers oncologists biopharmaceutical industry patient outcomes hospital & health care health wellness & fitness b2b

CB

Chip Baird Chief Executive Officer at 2seventy bio at 2seventy bio

JL

Jason Loveridge CEO at 4SC AG

MM

Marie Moores Chief Operating Officer at AB Cavalli Coach & Consultant

JR

Julie Rubinstein President and Chief Operating Officer at Adaptive Biotechnologies Corp.

CH

Chris Harano President and CEO at Advanced BioCatalytics

Outreach Guidance — biotechnology Sector

Technology executives make decisions on infrastructure, tooling, and partnerships. When reaching out to Ben Beneski, lead with your value proposition relative to the stack they currently use. Generic pitches perform poorly; specific technical relevance is key.

How do I reach Ben Beneski directly?

Ben Beneski's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Technical Officer (CTO) at Allogene Therapeutics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Ben Beneski work for?

Ben Beneski is Chief Technical Officer (CTO) at Allogene Therapeutics, a company in the biotechnology sector with 260.0 employees. The company is based in San Francisco, California.

Can I pitch or sell to Ben Beneski?

As Chief Technical Officer (CTO) at Allogene Therapeutics, Ben Beneski is a key decision-maker in the biotechnology sector. MessageCEO Pro gives you verified email to reach Ben Beneski directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Ben Beneski in?

Ben Beneski works in the biotechnology industry as Chief Technical Officer (CTO) at Allogene Therapeutics. MessageCEO provides verified contact information for executives across all major industries.

Is Ben Beneski's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Ben Beneski's profile is kept up-to-date with the latest available information.

Last updated: May 11, 2026